N/A N=68 Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Virus Diseases · Herpes Zoster
Primary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 VircapSeq Virus Detection in Sézary Syndrome
Lymphoma, T-Cell, Cutaneous · Sézary Syndrome
Primary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants
N/A N=82 Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
Phase 1 N=315 Live Enterovirus Vaccine and Type 1 Diabetes
Enterovirus Infection · Type 1 Diabetes · Prediabetic State
Primary: Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — 17; 2 Participants
Phase 3 N=26 Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 4 N=78 The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Phase 3 N=36 Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
Varicella
Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample
Phase 2 N=23 Viral Therapy in Treating Patients With Metastatic Melanoma
Recurrent Melanoma · Stage IV Melanoma
Primary: Tumor Response — 0; 0 participants
Phase 2 N=46 Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
Phase 1 N=513 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
N/A N=335 BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Phase 3 N=210 Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
Double-stranded DNA Virus
Primary: Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus — 15; 18; 39; 13 Participants
N/A N=300 Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants
Phase 2 N=120 Anti-viral Therapy in Alzheimer's Disease
Alzheimer Disease · Herpes Simplex 1 · Herpes Simplex 2
Primary: Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, Modified Version) Score — 20.6; 19.2; 30.2; 25.3 score on a scale — p=<0.05
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
N/A N=185 Observational Research on Infectious Disease Outbreaks and Difficult Cases of Unidentified Etiology in Indonesia
Infectious Disease
Primary: Confirm Etiologies Among Suspected COVID-19 Cases — 151; 21; 13 Participants
Phase 1 N=10 ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
Phase 2 N=354 A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
Herpes Zoster
Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 1.57 Ratio — p=<0.0001
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 3 N=17 BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
HIV · Salivary Gland Disease · Benign Lymphoepithelial Lesion
Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants
Phase 1 N=23 Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Anaplastic Astrocytoma · Anaplastic Oligodendroglioma · Mixed Glioma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 2 N=50 Valacyclovir for Mild Cognitive Impairment
Mild Cognitive Impairment · Herpes Simplex 1 · Herpes Simplex 2
Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants